ナトリウムチャネルブロッカーは,STセグメントの上昇と右ブランクバンドルブランクブロックの患者の突然死のリスクを特定しますが,構造的には正常な心臓です
R Brugada1, J Brugada, C Antzelevitch
1Department of Cardiology, Baylor College of Medicine, Houston, Texas, USA.
Circulation
|February 9, 2000
まとめ
ナトリウムチャネルブロッカーはブルガダ症候群を効果的に明らかにし,突然死のリスクのある患者を特定します. ブルガダ症候群の患者における一時的なまたは持続的なEKGの変化は,類似の心律不全のリスクを示します.
科学分野:
- 心臓病学 心臓病学
- 遺伝学 遺伝学とは
- 電気生理学 電気生理学
背景:
- ブルガダ症候群は,SCN5A変異と関連しており,右束のブランクブロック,STセグメントの上昇,突然死を引き起こす.
- ブルガダ症候群における心電図の変化は,しばしば一時的であり,リスクの階層化を複雑にする.
- アリズム障害のリスクのある患者を特定することは,ブルガダ症候群の管理に不可欠です.
研究 の 目的:
- 露面的および隠されたブルガダ症候群の患者における不律性リスクの評価.
- ブルガダ症候群を明らかにし,リスクのある個人を特定するために,ナトリウムチャネルブロッカーの有効性を評価する.
主な方法:
- ブルガダ症候群を患った34人の患者,SCN5A変異を患った家族11人,対照群53人を研究した.
- 静脈内でのアジャマリン,プロカイナミド,またはフレカイニドを投与して,EKGの変化を評価する.
- アリズム障害の発生率を比較するために,最大37ヶ月間,患者を追跡した.
主要な成果:
- ナトリウムチャネルブロッカーは,ブルガダ症候群とSCN5A変異の患者で特徴的なECG変化 (STセグメントの上昇,右束の枝のブロック) を誘発した.
- コントロール群や変異陰性家族では同様のEKGの変化は観察されなかった.
- 短期間的なECG症状と持続的なECG症状の患者の間で,不律症の発生率に有意な差は認められなかった.
結論:
- ナトリウムチャネルブロッカーは,ブルガダ症候群を明らかにし,リスクの高い患者を特定するのに役立ちます.
- 暫定的および持続的なブルガダ症候群のフェノタイプは,潜在的に致命的な心律不整症の同様のリスクを伴う.
- 早期発見とリスクの分層化は,ブルガダ症候群の管理の鍵となります.
さらに関連する動画
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
関連する概念動画
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...